Chabiotech Co.,Ltd. (KOSDAQ:085660)
South Korea · Delayed Price · Currency is KRW 17,600
+230 (1.32%)
Apr 10, 2026, 3:30 PM KST
Chabiotech Revenue
In the year 2025, Chabiotech had annual revenue of 1.27T KRW with 21.36% growth. Chabiotech had revenue of 346.54B in the quarter ending December 31, 2025, with 25.57% growth.
Revenue
1.27T
Revenue Growth
+21.36%
P/S Ratio
1.28
Revenue / Employee
4.56B
Employees
278
Market Cap
1.63T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.27T | 223.20B | 21.36% |
| Dec 31, 2024 | 1.05T | 91.10B | 9.55% |
| Dec 31, 2023 | 953.95B | 109.37B | 12.95% |
| Dec 31, 2022 | 844.58B | 117.11B | 16.10% |
| Dec 31, 2021 | 727.48B | 62.76B | 9.44% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SK bioscience | 651.37B |
| PharmaResearch | 536.29B |
| Hugel | 425.11B |
| MEDIPOST | 73.66B |
| Onconic Therapeutics | 53.39B |
| Pharmicell | 23.94B |
| OliX Pharmaceuticals | 14.67B |
| GI Innovation | 5.84B |